Illuminating Precision Oncology - From First Signal to Broad Impact, with Speed and Efficiency

Jeffrey A. Bacha B.Sc., M.B.A.

Jeffrey A. Bacha B.Sc., M.B.A.

Chief Executive Officer and Board Member​

Mr. Bacha has more than 25 years of experience in pharmaceutical research, corporate development, financing and executive leadership, having served as a founder, senior executive and director of multiple public and private life sciences companies.

Mr. Bacha co-founded DelMar Pharmaceuticals (now TuHURA Biosciences, Inc.; NASDAQ: HURA) with Dr. Dennis Brown and served as Chairman and Chief Executive Officer during the company’s growth, including its NASDAQ listing and the advancement of its lead product candidate into pivotal Phase III clinical development. He also co-founded Rakovina Therapeutics Inc. (TSX-V: RKV) with Dr. Brown and served as Chairman from 2021 to 2026.

Mr. Bacha served on the Board of Directors of Sernova Corp. (TSX-V: SVA) from 2006 to 2023. Earlier in his career, he was founding Chief Financial Officer of XBiotech, Inc. (NASDAQ: XBIT), founding Chief Executive Officer of Inimex Pharmaceuticals, and Vice President of Corporate Development at Inflazyme Corp. Drug development programs originating at Inimex and Inflazyme subsequently became important components of the development pipelines of Soligenix, Inc. (NASDAQ: SNGX) and Aquinox Pharmaceuticals (formerly NASDAQ: AQXP), respectively.

Mr. Bacha has also served as a member of the National Brain Tumor Society Research Roundtable and on the Board of the Leukemia & Lymphoma Society of Canada. He currently serves as a consultant to Valent Technologies LLC and as a member of the Board of Directors of Sera Biopharma, Inc.

Prior to assuming operating leadership roles in the biotechnology industry, Mr. Bacha served as a Senior Manager and Director with KPMG Health Ventures, where he advised numerous public and private life sciences companies on corporate development, financing and strategic initiatives.

Mr. Bacha holds an M.B.A. (Honors) from Emory University’s Goizueta Business School (1995) and a degree in Biophysics from the University of California, San Diego (1991). He is an inventor or co-inventor on multiple issued U.S. patents and patent applications, many of which have corresponding foreign counterparts.

Back to top Drag

John K. Bell

Independent Board Member

John K. Bell serves as lead independent director and chair of the audit committee.

Mr. Bell is the founder of Shred-Tech Ltd. and Polymer Technologies, Inc., John K. Bell is a businessperson who has been the head of 15 different companies and presently is Chairman at CrossChasm Technologies, Inc., Chairman & Chief Executive Officer at Onbelay Investment Corp., Chairman for Stack Capital Group, Inc., lead independent director of Edison Oncology Holding Corp., and Director & Governor at Stratford Festival. He is also on the board of Stratford Shakespearean Festival of America.

Mr. Bell was a founding investor of Research in Motion (Blackberry) and previously held the position of Director at Canopy Growth Corp. and Chairman of Canopy Rivers Corp. (a subsidiary of Canopy Growth Corp.), Chairman of Waterloo Regional Police Service, Chairman of Prosperity Council of Waterloo Region, Director at RIV Capital, Inc., Chief Executive Officer & Director at ATS Corp., Chief Executive Officer & Owner at Shred-Tech Ltd., Director at BSM Technologies, Inc., Director at BSM Technologies Ltd., Chairman of HEXO Corp., President & Chief Executive Officer of Polymer Technologies, Inc., Chairman of Cambridge Memorial Hospital, Member of Institute of Corporate Directors and Secretary & Director at Crohn’s & Colitis Foundation of Canada.

John K. Bell received an undergraduate degree from Richard Ivey School of Business.